Financial News

Sanofi and Janssen join forces to develop E.coli vaccine, with Sanofi's $175M upfront payment

Sanofi revealed Tuesday that it had entered into an agreement with Janssen for the joint development and marketing of a vaccine candidate targeting extra-intestinal pathogenic E.coli.

Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.

Under the terms of the deal, both parties will co-fund current and future research and development costs. Sanofi will pay $175 million upfront to Janssen, followed by development and commercial milestones.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback